Delivery Order SPE2DB25D3110-SPE2DB25FTEAD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Menveo A-C-Y-W vaccine kits (2 vials) with a ceiling value of $1,342.88. This firm fixed-price delivery order, with an ultimate completion date of August 14, 2025, represents a routine pharmaceutical procurement supporting the federal medical supply chain. The contract was competitively awarded with no set-aside designation and will be performed at the vendor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $7,087.92 to AmerisourceBergen Drug Corp for Menveo A-C-Y-W Kit (2 vials) on August 4, 2025, with completion scheduled for August 5, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $1,342.88 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Menveo A-C-Y-W Kit (2 Vials), a meningococcal conjugate vaccine. The contract is structured as a firm fixed price delivery order with an ultimate completion date of July 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was used for this competitively awarded procurement. This...
- The Defense Logistics Agency awarded a delivery order valued at $5,677.70 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Menveo A-C-Y-W vaccine kits (2 vials). This is a firm fixed price delivery order with an ultimate completion date of July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a non-competitive award, indicating the product was procured through an existing contract vehicle rather than a new...
- The Defense Logistics Agency awarded a delivery order valued at $1,007.16 to AmerisourceBergen Drug Corp for the supply of Menveo A-C-Y-W vaccine kits (2 vials each). This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 24, 2025. The order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Menveo 1 vial (A-C-Y-W-135-DIP) 0.5mL vaccine, with a ceiling value of $6,449.00. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Menveo A-C-Y-W vaccine kits (2 vials) under a firm fixed price contract valued at $3,357.20. The order was competitively awarded with no set-aside designation and is scheduled for completion by August 13, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on July 28, 2025, for Menveo A-C-Y-W vaccine kits (2 vials) with a ceiling value of $13,567.88 under firm fixed-price terms. This non-set-aside contract is scheduled for completion by July 29, 2025, with performance taking place at the company's Conshohocken, Pennsylvania headquarters. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC SPE2DX)...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $13,397.27 on August 12, 2025, for the supply of Menveo 1 Vial-A-C-Y-W-135-DIP 0.5ML, a meningococcal vaccine. This firm fixed price delivery order, with an ultimate completion date of August 13, 2025, carries no set-aside designation and represents a competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Menveo 1 Vial A-C-Y-W-135-DIP 0.5ML, a meningococcal vaccine product. This firm fixed price delivery order, valued at $3,789.19, represents a competitively awarded contract with no set-aside designation and is scheduled for completion by July 31, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- SPE2DB25D3110Indefinite Delivery Contract
- SPE2DB25D3110-SPE2DB25FTEADDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Menveo A-C-Y-W vaccine kits (2 vials each) at a ceiling value of $1,310.92. This firm fixed price delivery order is non-set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania, with completion expected by August 6, 2025. The contract represents a routine pharmaceutical procurement under the Defense Logistics Agency's medical supply chain operations. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement needs, supplying vaccines, medications, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide. The company's role in the DLA Pharmaceutical Prime Vendor Global Program underscores its significance as a qualified provider meeting federal procurement requirements through competitive award processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 8/5/25 |